Evaluation of WT1 expression in bone marrow vs peripheral blood samples of children with acute myeloid leukemia - Impact on minimal residual disease detection

Leukemia

Volumn 27, Issue 5, 2013, Pages 1194-1196

  Kramarzova, K ^a   Boublikova, L ^a   Stary, J ^a   Trka, J ^a  

^a UNIVERSITY HOSPITAL MOTOL   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

WT1 PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; BLOOD SAMPLING; BONE MARROW; CHILD; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC VALUE; HUMAN; HUMAN CELL; LETTER; MAJOR CLINICAL STUDY; MINIMAL RESIDUAL DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SURVIVAL RATE; TUMOR SUPPRESSOR GENE;

BONE MARROW; CHILD; HUMANS; LEUKEMIA, MYELOID, ACUTE; NEOPLASM, RESIDUAL; TUMOR MARKERS, BIOLOGICAL; WT1 PROTEINS;

EID: 84877617855     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2012.291     Document Type: Letter

References (12)

1. Scharnhorst V, van der Eb AJ, Jochemsen AG. WT1 proteins: functions in growth and differentiation. Gene 2001; 273: 141-161.
2. Haber DA, Sohn RL, Buckler AJ, Pelletier J, Call KM, Housman DE. Alternative splicing and genomic structure of the Wilms tumor gene WT1. Proc Natl Acad Sci USA 1991; 88: 9618-9622.
3. Sugiyama H. Wilms' tumor gene WT1: its oncogenic function and clinical application. Int J Hematol 2001; 73: 177-187.
4. Wagner KD, Wagner N, Schedl A. The complex life of WT1. J Cell Sci 2003; 116 (Pt 9): 1653-1658.
5. Ariyaratana S, Loeb DM. The role of the Wilms tumour gene (WT1) in normal and malignant haematopoiesis. Expert Rev Mol Med 2007; 9: 1-17.
6. Trka J, Kalinova M, Hrusak O, Zuna J, Krejci O, Madzo J et al. Real-time quantitative PCR detection of WT1 gene expression in children with AML: prognostic significance, correlation with disease status and residual disease detection by flow cytometry. Leukemia 2002; 16: 1381-1389.
7. Willasch AM, Gruhn B, Coliva T, Kalinova M, Schneider G, Kreyenberg H et al. Standardization of WT1 mRNA quantitation for minimal residual disease monitoring in childhood AML and implications of WT1 gene mutations: a European multicenter study. Leukemia 2009; 23: 1472-1479.
8. Weisser M, Kern W, Rauhut S, Schoch C, Hiddemann W, Haferlach T et al. Prognostic impact of RT-PCR-based quantification of WT1 gene expression during MRD monitoring of acute myeloid leukemia. Leukemia 2005; 19: 1416-1423.
9. Cilloni D, Messa F, Arruga F, Defilippi I, Gottardi E, Fava M et al. Early prediction of treatment outcome in acute myeloid leukemia by measurement of WT1 transcript levels in peripheral blood samples collected after chemotherapy. Haematologica 2008; 93: 921-924.
10. Ommen HB, Nyvold CG, Braendstrup K, Andersen BL, Ommen IB, Hasle H et al. Relapse prediction in acute myeloid leukaemia patients in complete remission using WT1 as a molecular marker: development of a mathematical model to predict time from molecular to clinical relapse and define optimal sampling intervals. Br J Haematol 2008; 141: 782-791.
11. Kramarzova K, Stuchly J, Willasch A, Gruhn B, Schwarz J, Cermak J et al. Real-time PCR quantification of major Wilms' tumor gene 1 (WT1) isoforms in acute myeloid leukemia, their characteristic expression patterns and possible functional consequences. Leukemia 2012; 26: 2086-2095.
12. Boublikova L, Kalinova M, Ryan J, Quinn F, O'Marcaigh A, Smith O et al. Wilms' tumor gene 1 (WT1) expression in childhood acute lymphoblastic leukemia: a wide range of WT1 expression levels, its impact on prognosis and minimal residual disease monitoring. Leukemia 2006; 20: 254-263.